KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt to Equity (2019 - 2025)

Historic Debt to Equity for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $0.92.

  • Royalty Pharma's Debt to Equity rose 2517.69% to $0.92 in Q4 2025 from the same period last year, while for Dec 2025 it was $0.92, marking a year-over-year increase of 2517.69%. This contributed to the annual value of $0.92 for FY2025, which is 2517.69% up from last year.
  • Latest data reveals that Royalty Pharma reported Debt to Equity of $0.92 as of Q4 2025, which was up 2517.69% from $0.93 recorded in Q3 2025.
  • Royalty Pharma's 5-year Debt to Equity high stood at $0.93 for Q3 2025, and its period low was $0.57 during Q2 2021.
  • For the 5-year period, Royalty Pharma's Debt to Equity averaged around $0.72, with its median value being $0.72 (2023).
  • In the last 5 years, Royalty Pharma's Debt to Equity plummeted by 1856.41% in 2023 and then surged by 2538.61% in 2025.
  • Over the past 5 years, Royalty Pharma's Debt to Equity (Quarter) stood at $0.7 in 2021, then rose by 6.28% to $0.75 in 2022, then dropped by 18.56% to $0.61 in 2023, then grew by 20.98% to $0.74 in 2024, then rose by 25.18% to $0.92 in 2025.
  • Its last three reported values are $0.92 in Q4 2025, $0.93 for Q3 2025, and $0.84 during Q2 2025.